CrossAssetDataThe Company File
···
SLGL

Sol-Gel Technologies Ltd.

Sol-Gel Technologies Ltd. is classed by the SEC under Pharmaceutical Preparations (industry code 2834). In its latest annual figures on file, for the fiscal year ended 2025-12-31, it reported revenue of $19 million and a loss of $6 million (its filed statements).

Pre-revenue company Pharmaceutical Preparations filings since 2016 7 of 9 filed, 2 estimated
Ask the desk about SLGL → Compare SLGL with VERU → Price chart on TradingView ↗ Full EDGAR file ↗ Watch SLGL →

Sector peers: VERUTLPHPDSBCPHI

6.5/10headline grade
vs its business-model standard
7.3/10past 6.4/10present 6.1/10future

Three tenses, nine metrics. Unseen metrics stay unseen; the grade never fakes a number. Proxy era: provisional values, marked. Weighed as a pre-revenue company: no meaningful revenue on file yet (industry code 2834), so it is read as a pre-revenue company; the filing read can change it. All three tenses have at least two readings, so the archetype blend applies as printed.

The grade, in three tenses

Headline 6.5 out of ten, 7 of 9 metrics filed and 2 estimated: past 7.3 out of ten, present 6.4 out of ten, future 6.1 out of ten. The past asks what it actually did, the present what it is doing right now, the future what it is set up to do next.

The nine metrics

  • Surviving crises (past): 8.2 out of ten. No warning events in its filings since 2017. 82nd percentile among 497 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
  • Track record (past): 5.3 out of ten. +80.2% a year over 9 filed years; profitable in 1 of 9. 54th percentile among 324 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
  • Shareholder treatment (past): 9.5 out of ten. CrossAssetData estimate 9.5/10, confidence 35 of 100 (one part). 95th percentile among 463 sector filers. A CrossAssetData estimate, not a filed reading: one part, confidence 35 of 100; a filing that carries the missing parts replaces this estimate with the filed reading.
  • Financial health (present): 7.4 out of ten. ROE -27%: lost 27¢ per shareholder dollar. Leverage 24%: owes 24¢ per asset dollar. 74th percentile among 472 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
  • Industry position (present): 6.4 out of ten. top 36% of 314 in its family; net margin -31.6%. 64th percentile among 314 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
  • Leadership (present): 5.0 out of ten. CrossAssetData estimate 5.0/10, confidence 20 of 100 (family median). 50th percentile among 371 sector filers. A CrossAssetData estimate, not a filed reading: family median, confidence 20 of 100; its next annual report on file with the inputs replaces this estimate with the filed reading.
  • Room to expand (future): 6.1 out of ten. top 39% of 272 in its family for room to expand. 61st percentile among 272 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
  • Growth drivers (future): 5.7 out of ten. top 43% of 307 in its family for growth drivers. 57th percentile among 307 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
  • Expectations vs reality (future): 6.8 out of ten. top 32% of 234 in its family for expectations against reality. 68th percentile among 234 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).

The filing record

Newest annual report: Form 20-F filed 2026-03-19 for the period ended 2025-12-31 (on EDGAR). Newest filing: Form 6-K, 2026-10-06. Filings on record since 2016. Read from EDGAR 2026-10-12.

Where the revenue comes from

Product and service lines in fiscal 2025: License 96%, Royalty 4%, Service Other under 1%. By geography: United States 86%, Canada 9%, Switzerland 4%, Other 1%, China under 1%. As tagged in its annual report (Form 20-F, filed 2026-03-19).

Who runs it

Arkin, Moshe (Chairman of Board and CEO); Ben-Or, Eyal (Chief Financial Officer); Yosef, Itzik (Chief Operating Officer); Glezin, Michael (Chief Business Officer); Levy-Hacham, Ofra (VP Clinical, Reg & Quality); Toledano, Ofer (VP Research & Dev.); Arkin, Itai Gidon (director); Gottfried, Ran (director); Kochan, Sharon (director); Lerman, Hanna (director); and 1 more. 11 officers and directors have filed their own trades in the last fifteen months, names and titles as filed with the SEC, through 2026-09-30.

This file: Overview · Past · Present · Future · Filings · every company on file

Every stock is a company. We grade the company behind the stock. CrossAssetData is a company research product: no investment advice, no price targets, no price predictions; every claim carries its source, and unseen means unseen. The full file draws when the page's script runs: the essentials, the balance sheet, the estimators, the trend, and every filing of the last ten years.